Aditxt, Inc.
Close on Oct 19, 2026
- Market cap
- $20
- P/E (TTM)
- –
- Dividend yield
- –
About Aditxt
Pharmaceutical Preparations, SIC 2834
Aditxt, Inc. operates as a health innovation platform dedicated to developing and commercializing therapeutic and diagnostic solutions across its specialized operating subsidiaries. Through Adimune, Inc., the company develops Apoptotic DNA Immunotherapy technologies, led by its ADI-100 drug candidate targeting type-1 diabetes, psoriasis, and rare autoimmune disorders such as Stiff Person Syndrome. Its Pearsanta, Inc. subsidiary focuses on early cancer detection and non-invasive liquid biopsies utilizing mitochondrial DNA and DNA adduct technologies, developing screening tests for prostate cancer and endometriosis alongside immune profiling platforms. Additionally, the company advances antimicrobial solutions through Adivir, Inc. and women's health initiatives through Adifem, Inc. The company's innovations serve individuals, healthcare providers, and the medical community.
The company maintains its corporate headquarters in Mountain View, California. Pearsanta leases a certified high-complexity laboratory in Richmond, Virginia, while Adimune coordinates manufacturing and upcoming clinical trials across the United States and Germany.
Summary of the business section of Aditxt's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aditxt, Inc.
- Founded
- 2017
- Headquarters
- Richmond, VA
- Address
- 737 N. Fifth Street, Suite 200 23219
- Phone
- (909) 488-0844
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- dbbmckennon, San Diego, California
Stock & identifiers
- Ticker
- ADTX
- Exchange
- OTC
- IPO date
- Jul 1, 2020
- Shares outstanding
- 1M, May 20, 2026
- Public float
- $4.32M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-27 reverse, May 18, 2026; 1-for-8 reverse, Mar 9, 2026; 1-for-113 reverse, Nov 3, 2025; 1-for-250 reverse, Mar 17, 2025; 1-for-40 reverse, Nov 18, 2024; 1-for-40 reverse, Oct 2, 2024; 1-for-40 reverse, Nov 14, 2023; 1-for-40 reverse, Aug 18, 2023; 1-for-50 reverse, Nov 14, 2022; 1-for-50 reverse, Sep 14, 2022
- SEC CIK
- 1726711
- CUSIP
- 007025869
- ISIN
- US0070258696
- LEI
- 529900NYTSP9EB7RD741
- EIN
- 82-3204328
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Corinne Pankovcin | Chief M&A Officer | 0 |
| Christopher Jon Porcelli | General Counsel, CPO & CS | 0 |
| Brian Michael Brady | Director | 3 |
| Sylvia Hermina | Director | – |
| Saundra L. Pelletier | Director | – |
Corporate history
Events identified from SEC filings